The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 36 results
Sort by date: Descending
Encores: Not included
US Psych Congress Annual
September 7th – 10th 2023
Alcohol Use Disorder
Non-specific
Opioid Use Disorder
POSTER
Opioid Antagonists: Clinical Utility, Pharmacology, and Safety and Tolerability
AUTHOR(S)

Roger S. McIntyre,1 Marni White,2 Mark S. Todtenkopf,2 Sarah Akerman,2 Joshua Burgett3

View poster
Alcohol Use Disorder
Non-specific
Opioid Use Disorder
Schizophrenia
POSTER
Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Factor Scores in the ALPINE Study
AUTHOR(S)

Leslie Citrome,1 James A. McGrory,2 Martin Dunbar2

View poster
Schizophrenia
Schizophrenia
POSTER
Treatment Patterns From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
AUTHOR(S)

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

View poster
Schizophrenia
Schizophrenia
POSTER
Key Characteristics of the Atypical Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Schizophrenia
AUTHOR(S)

Leslie Citrome,1 Christoph U. Correll,2-4 Gregory W. Mattingly,5 Andrew J. Cutler,6 Amber R. Hoberg,7 Peter J. Weiden,8 Bhaskar Rege,9 James A. McGrory,9 Martin Dunbar,9 Craig Hopkinson,9 David McDonnell10

View poster
Schizophrenia
Sleep-wake disorders
POSTER
Diagnosis and Symptoms of Narcolepsy From the Patient Perspective: Results From In-Depth Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 Wilbur P. Williams, III1

View poster
Sleep-wake disorders
Schizophrenia
POSTER
Outcomes From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
AUTHOR(S)

Lauren N. Strand,1 Michael J. Doane,1 Christina Arevalo,1 James A. McGrory,1 Peter J. Weiden,2 Eric D. Achtyes,3 Phillip D. Harvey,4 John M. Kane,5 Stephen R. Saklad,6 Jeffrey Trotter,7 Dawn I. Velligan8

View poster
Schizophrenia